Aurinia Pharmaceuticals (AUPH) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunome (IMNM) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 38.2% versus a gain of 36.7%. Over five years, IMNM leads with a +8.4% price change compared with -22.2% for AUPH. Immunome is the larger company by market cap ($2.25 billion vs $2.13 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | IMNM |
|---|---|---|
| Share price | $16.01 | $19.10 |
| Market cap | $2.13B | $2.25B |
| 1-day change | +2.04% | -1.11% |
| YTD return | +0.38% | -11.10% |
| 1-year return | +36.72% | +38.17% |
| 5-year return | -22.17% | +8.43% |
| P/E ratio (TTM) | 7.02 | — |
| Forward P/E | 15.01 | — |
| EPS (TTM) | $2.28 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $30.06 |
| 52-week low | $10.90 | $13.49 |
| Distance from 52-week high | -16.83% | -36.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +11.56% | +84.34% |
| Average volume | 988.90K | 1.19M |
| Shares outstanding | 133.05M | 118.00M |
| Employees | 128 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
AUPH vs IMNM FAQ
Which is bigger, Aurinia Pharmaceuticals or Immunome?
Immunome (IMNM) is larger, with a market capitalization of $2.25B compared with $2.13B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or IMNM?
IMNM returned +38.17% over the past 12 months, compared with +36.72% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.